(Q40314116)

English

A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Simtuzumab in Combination with FOLFIRI for the Second-Line Treatment of Metastatic KRAS Mutant Colorectal Adenocarcinoma

scientific article published on 28 February 2017

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

19 September 2017

A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Simtuzumab in Combination with FOLFIRI for the Second-Line Treatment of Metastatic KRAS Mutant Colorectal Adenocarcinoma (English)

1 reference

Europe PubMed Central

PMC publication ID

19 September 2017

1 reference

based on heuristic

inferred from title

author name string

J Randolph Hecht

1

1 reference

Europe PubMed Central

PMC publication ID

19 September 2017

Al B Benson

2

1 reference

Europe PubMed Central

PMC publication ID

19 September 2017

Dmitry Vyushkov

3

1 reference

Europe PubMed Central

PMC publication ID

19 September 2017

Yingsi Yang

4

1 reference

Europe PubMed Central

PMC publication ID

19 September 2017

Johanna Bendell

5

1 reference

Europe PubMed Central

PMC publication ID

19 September 2017

Udit Verma

6

1 reference

Europe PubMed Central

PMC publication ID

19 September 2017

publication date

28 February 2017

1 reference

Europe PubMed Central

PMC publication ID

19 September 2017

1 reference

Europe PubMed Central

PMC publication ID

19 September 2017

22

1 reference

Europe PubMed Central

PMC publication ID

19 September 2017

3

1 reference

Europe PubMed Central

PMC publication ID

19 September 2017

243-e23

1 reference

Europe PubMed Central

PMC publication ID

19 September 2017

Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5344646

22 September 2017

Lysyl oxidase-like-2 promotes tumour angiogenesis and is a potential therapeutic target in angiogenic tumours

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5344646

22 September 2017

KRAS-mutation status in relation to colorectal cancer survival: the joint impact of correlated tumour markers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5344646

22 September 2017

Genetic alterations in colorectal cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5344646

22 September 2017

The role of tumor stroma in cancer progression and prognosis: emphasis on carcinoma-associated fibroblasts and non-small cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5344646

22 September 2017

Allosteric inhibition of lysyl oxidase–like-2 impedes the development of a pathologic microenvironment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5344646

22 September 2017

Modulation of lysyl oxidase-like 2 enzymatic activity by an allosteric antibody inhibitor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5344646

22 September 2017

Secreted LOXL2 is a novel therapeutic target that promotes gastric cancer metastasis via the Src/FAK pathway

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5344646

22 September 2017

Paradoxical roles for lysyl oxidases in cancer--a prospect

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5344646

22 September 2017

Lysyl oxidase-like 2 expression is increased in colon and esophageal tumors and associated with less differentiated colon tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5344646

22 September 2017

Stromal fibroblasts in cancer initiation and progression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5344646

22 September 2017

The role of LOX and LOXL2 in scar formation after glaucoma surgery.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5344646

20 August 2018

Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5344646

20 August 2018

Identifiers

10.1634/THEONCOLOGIST.2016-0479

1 reference

Europe PubMed Central

PMC publication ID

19 September 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

19 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

19 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40314116&oldid=1895013567"